ArticleMedComm2026

Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non-Small Cell Lung Cancer: A Multicenter Real-World Study.

Siqi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.